Holen Sie sich die Stockscreener-App
3.73
0.27%
0.010
Vorhandelsmarkt:
3.80
0.07
+1.88%
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Fulcrum Therapeutics Inc (FULC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey
Kaplan Fox Launches Securities Probe Into Fulcrum Therapeutics After Pociredir Program Halt Sparks Stock Plunge - Kalkine Media
Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ETFs Investing in Fulcrum Therapeutics, Inc. Stocks - TradingView
Fulcrum Therapeutics Inc (FULC) Cash Flow - TradingKey
FULC|Fulcrum Therapeutics Inc|Price:3.725|Chg%:+0.005 - TradingKey
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation - TMX Newsfile
Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: F - The National Law Review
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law ViolationsInvestors are Encouraged to Contact the Firm - FinancialContent
TANG CAPITAL MANAGEMENT LLC Increases Stake in Fulcrum Therapeutics Inc. - GuruFocus
Kaplan Fox Announces an Investigation Into Fulcrum Therapeutics - The National Law Review
Fulcrum Therapeutics 10% owner Kevin Tang acquires $594,132 of common shares - Bitget
Fulcrum Therapeutics: director Kevin Tang buys $594k in shares By Investing.com - Investing.com Australia
Form 4 Fulcrum Therapeutics Inc For: 21 July By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics: director Kevin Tang buys $594k in shares - Investing.com
Fulcrum Therapeutics, Inc. (FULC) insider funds purchase 167,616 shares at ~$3.5 - Stock Titan
If You Invested $1,000 in Fulcrum Therapeutics (FULC) - Stock Titan
Fulcrum Therapeutics stock plunges 51% after ha... - Pluang
Kaplan Fox Initiates Probe Into Fulcrum Therapeutics Over Securities Issues After Pociredir Program Halt - Kalkine Media
Fulcrum Therapeutics (FULC) Q1 2026 Earnings: Narrower-Than-Anticipated Loss as Pre-Revenue Biotech Advances PipelineNew Analyst Coverage - dars.gov.et
Kaplan Fox Initiates Securities Probe into Fulcrum Therapeutics After 51% Stock Plunge Post-Pociredir Program Halt - Kalkine Media
BlackRock Portfolio Management LLC discloses 6.0% holding in THERAPEUTICS INC (FULC) - Stock Titan
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Form 4 Fulcrum Therapeutics Inc For: 15 July By Investing.com - Investing.com South Africa
Kaplan Fox & Kilsheimer LLP Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to a Securities Investigation - NewMediaWire
Kevin Tang buys $891k of Fulcrum Therapeutics stock By Investing.com - Investing.com Canada
Kevin Tang buys $891k of Fulcrum Therapeutics stock - Investing.com
Fulcrum Therapeutics, Inc. (FULC) gains Tang Capital as 10.4% shareholder - Stock Titan
Fulcrum Therapeutics (FULC) holder adds 249,946 shares in open-market buys - Stock Titan
Fulcrum Therapeutics (FULC) insider reports 6,663,383-share Tang Capital stake - Stock Titan
Frontier tech research, news & data - MLQ.ai
Fulcrum Therapeutics (FULC) loses 51% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Fulcrum Therapeutics (FULC) Slides 3.7% as Sellers Test Key Support Near $3.45Charm Flow - dars.gov.et
Fulcrum Therapeutics Inc. (FULC) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Market ReactionRevenue Surprise History - dars.gov.et
Fulcrum Therapeutics (FULC) director awarded 32,000 options at $3.66 - Stock Titan
Fulcrum Therapeutics (FULC) director awarded 32,000 stock options - Stock Titan
Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike - Stock Titan
Fulcrum Therapeutics (FULC) director granted 32,000 stock options at $3.66 strike - Stock Titan
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K. - Moomoo
After plunging 21.5% in 4 weeks, here's why the trend might reverse for Fulcrum Therapeutics (FULC) - MSN
Fulcrum Therapeutics | 8-K: Current report - Moomoo
Insider Sell Alert: Alan Ezekowitz Sells 18,000 Shares of Fulcru - GuruFocus
Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan - Stock Titan
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000E Growth Benchmark - marketscreener.com
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - Eastern Progress
Price to sales forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Price to earnings forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):